News

AbstractAcoramidis is a novel transthyretin stabilizer recently approved for the treatment of transthyretin amyloid cardiomyopathy. Although clinical trials showed…

Aims To evaluate the applicability of the RoMa classification in patients with transthyretin cardiac amyloidosis (ATTR-CM) and to assess its association with…

AbstractBackground: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive infiltrative cardiomyopathy associated with substantial morbidity and mortality…

Background and Objectives: Amyloidosis is a systemic disorder characterized by extracellular deposition of misfolded protein fibrils, most commonly light-chain (AL…

Vutrisiran demonstrated consistent efficacy in both women and men with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), with no statistically significant…

AbstractIntroductionIgD-associated AL amyloidosis is a rare subtype, accounting for 1–2% of cases, with fewer than 100 reported. Prior studies show inconsistent…

AbstractBackgroundTransthyretin cardiac amyloidosis (ATTR-CM) is a progressive, underdiagnosed cause of heart failure (HF). Diagnostic delays may increase cardiac…

AbstractBACKGROUND:Technetium-based cardiac amyloid radionuclide imaging enables noninvasive diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM), but…

Long-term treatment with the experimental therapy candidate cliramitug safely and effectively reduces toxic clumps of the transthyretin (TTR) protein and heart…

Join this 30-minute Cardio Town Hall, moderated and led by Dr. Mazen Hanna and Dr. Mathew Maurer for an expert discussion on contemporary ATTR-CM clinical research…